SGLT2 Inhibitor

Dapagliflozin-d₄ (BMS-512148-d₄) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.

Sergliflozin-A is a compound used to inhibit type 2 diabetes. It can inhibit glucose transporters in the kidney, competitively inhibit hSGLT1 and hSGLT2, and mutations at different sites have different effects on its inhibitory effect.

Galacto-dapagliflozin is a selective inhibitor for hSGLT2 with K_i of 25 nM.

SGLT2-IN-4 (Compound 1) is a selective and orally active sodium-dependent glucose cotransporter-2 (SGLT2) inhibitor. SGLT2-IN-4 can increase the proportion of protein α-helix and enhance the stability of the SGLT2-D201A mutant. SGLT2-IN-4 can be used for the research of type 2 diabetes.

fluoro-Dapagliflozin, a structural analog of Dapagliflozin, is a selective SGLT2 inhibitor with K_i values of 5.3 nM and 330 nM for SGLT2 and SGLT1, respectively. fluoro-Dapagliflozin blocks glucose transport and glucose-coupled currents.